Pipeline

Pipeline

Kala is developing a diversified pipeline of ophthalmic product candidates with its most advanced clinical programs targeting dry eye disease and post-surgical ocular inflammation and pain. In addition, Kala is developing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program for potential topical treatment of wet age-related macular degeneration (AMD) and other retinal diseases.

KalaPipeline_23Jul2015